5 CMC Strategy Mistakes That Delay IND Filings — And How to Avoid Them

1. Underestimating comparability requirements when scaling up

Moving from lab-scale to GMP batches almost always changes something — a raw material source, a piece of equipment, a process parameter. Teams that don't plan a comparability strategy early often find themselves scrambling to justify why their clinical batch differs from earlier material, which can trigger additional testing or FDA questions late in the process.

2. Treating CMC as a checkbox instead of a strategic conversation

A CMC package that simply satisfies the letter of the guidance, without anticipating the specific questions a reviewer will have about your molecule or platform, invites additional review cycles. The strongest packages are built around a dialogue with the agency, not just a submission.

3. Designing the stability program too late

Stability data takes time to generate — there's no way to compress it after the fact. Programs that wait until CMC sections are being drafted to finalize a stability protocol often end up with gaps that delay filing or limit the shelf-life claims they can support at launch.

4. Setting specifications without tying them to clinical use

Specifications should be justified by what's actually needed for the intended dose, patient population, and route of administration — not just by what a given batch happened to measure. Specifications set too tightly, or too loosely, both create problems: the former invites manufacturing failures, the latter invites regulatory pushback.

5. Bringing in regulatory/CMC expertise too late to matter

By the time a pre-IND meeting package is being finalized, many of the highest-leverage strategic choices have already been made. Engaging experienced regulatory and CMC advisors earlier — ideally while the development plan is still being shaped — means that expertise can influence the plan itself, not just polish the paperwork around it.

None of these mistakes are exotic. They're the ordinary, avoidable friction points that turn a straightforward IND timeline into a stressful one. A second set of experienced eyes on CMC and regulatory strategy — before the plan is locked in — is often the difference between filing on schedule and filing six months late.

At Precise X Med (PXM Biologics), we provide senior regulatory affairs, CMC, and strategic advisory support to biotech and pharma companies navigating exactly these inflection points, drawing on 30+ years of combined regulatory and CMC experience, including former FDA reviewers.